Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has enrolled the first patient in its exploratory Phase I clinical trial of RX-3117 in cancer patients.
Subscribe to our email newsletter
The study will evaluate the oral bioavailability of RX-3117 in humans.
The company will continue the enrollment through the first half of 2012 and expects to release the preliminary in second half of 2012.
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis.
Rexahn president Rick Soni said RX-3117 has demonstrated good safety profile in preclinical studies, providing the compound with potential applications in a range of solid tumors.